How Selegiline ((-)-Deprenyl) Slows Brain Aging

About the eBook

This eBook is a useful reference for graduate medical students, academic researchers in the field of neuropsychopharmacology, neurophysiology and gerontology and professional research groups in commercial organizations manufacturing selegiline preparations.

Contents

- (-)-Deprenyl (Selegiline), The First Selective Inhibitor of B-Type MAO and the Unique One Free of the Cheese Effect
- The Catecholaminergic Activity Enhancer Effect of (-)-Deprenyl and R-(±)-1-(Benzofuran-2-yl)-2-Propylaminopentane ([-]-BPAP)
- The Catecholaminergic Control of the Uphill and Downhill Period of Life
- The Antioxidant and Neuroprotective Effect of (-)-Deprenyl and their Relation to the Enhancer Effect
- Benefits of Selegiline in the Treatment of Parkinson’s Disease (PD)
- Benefits of Selegiline in the Treatment of Alzheimer’s Disease (AD)

For Sales Advertising Inquiries: Contact: marketing@benthamscience.org